Healing Advocacy Fund

What Healing Advocacy Fund does

Healing Advocacy Fund (HAF) is a 501c3 nonprofit organization (Federal Tax ID 85-4388263) whose mission is to expand and protect safe, affordable state-regulated access to psychedelic healing. It serves individuals with treatment-resistant depression, anxiety, substance use disorder, PTSD, and end-of-life distress; licensed facilitators and service centers operating under state-regulated psilocybin programs; and healthcare providers who need education and referral pathways. The organization is the leading advocacy body across the three U.S. jurisdictions that have enacted state-regulated psilocybin therapy frameworks: Oregon (Measure 109, voter-approved 2020, program launched 2023), Colorado (Proposition 122 / Natural Medicine Health Act, passed 2022, program launched 2025), and New Mexico (Medical Psilocybin Act, signed into law on June 20, 2025).

HAF's core offerings are not software products but a curated portfolio of advocacy, education, and ecosystem resources. Its primary platform is healingadvocacyfund.org, which hosts state-specific program information for Oregon, Colorado, and New Mexico; client education guides; service center and facilitator directories; a continuing education directory for practitioners; a media resources page; a webinar archive; and an email newsletter. The organization also operates a donation portal hosted on Givebutter. HAF's technology footprint is a content-and-resource website built on Squarespace, with no proprietary software, APIs, SDKs, or AI components disclosed.

HAF's business model is charitable donation-funded rather than commercial. The organization does not charge for its services and generates revenue primarily through charitable contributions from individuals and family foundations. Its go-to-market motion is community-led: policy advocacy, direct outreach to patients and healthcare providers, webinar and event programming, and earned-media coverage in outlets including CNN, CNBC, The Guardian, the New York Times, and NPR. HAF is governed by an Executive Director (Taylor West) and supported by state-level directors for Colorado (Tasia Poinsatte) and New Mexico (Denali Wilson, hired 2025). The organization is operationally embedded in a coalition of academic, clinical, and regulatory partners, including Oregon Health & Science University's OPEN Initiative, People Science, InnerTrek, the Psychedelic Safety Institute, the Colorado Department of Public Health and Environment, the University of New Mexico, and the Psychedelic Mental Health Access Alliance.

Name

Healing Advocacy Fund

Legal name

Healing Advocacy Fund

Website

https://healingadvocacyfund.org

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Healing Advocacy Fund is a 501c3 nonprofit that advocates for safe, affordable state-regulated access to psilocybin therapy, serving patients with depression, anxiety, substance use disorder, and end-of-life distress, plus licensed facilitators and clinicians across Oregon, Colorado, and New Mexico.

Ownership category

akta.pro rank

Product category

Psychedelic Therapy Advocacy

NAICS

Voluntary Health Organizations (813212), Social Advocacy Organizations (8133)

SIC

Services-Health Services (8000), Services-Social Services (8300)

akta.pro primary industry

Mental Health & Crisis Support Services (BPAGACAD)

akta.pro secondary industries

Palliative Care, Hospice & Serious Illness Support (BPAGACAK), Legal Aid & Client Advocacy Services (BPAGAEAM)

Keywords

• Psychedelic therapy advocacy
• Psilocybin policy reform
• State-regulated psychedelics
• Nonprofit health advocacy
• Psychedelic safety standards

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Charitable Donations: Healing Advocacy Fund is a 501c3 nonprofit organization that generates revenue primarily through charitable donations from individuals, family foundations, and supporters who believe in expanding safe, equitable access to psilocybin therapy.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Healing Advocacy Fund is a 501c3 nonprofit advocacy organization that expands and protects safe, affordable state-regulated access to psychedelic healing. Its core offerings include policy advocacy, patient and provider education resources, client education guides, service center and facilitator directories, a continuing education directory for practitioners, webinars, and a newsletter focused on psilocybin therapy programs in Oregon, Colorado, and New Mexico.

Product overview

Healing Advocacy Fund is a 501c3 non-profit organization that operates primarily as an advocacy and educational resource organization rather than a software product company. Its offerings consist of its website platform (healingadvocacyfund.org) providing comprehensive information about state-regulated psychedelic therapy programs across Oregon, Colorado, and New Mexico. The organization provides educational client guides, service directories (service centers, healing centers, continuing education), news updates via newsletter, and a donation portal. The portfolio includes program-specific resources for each of the three states where regulated psychedelic therapy programs exist, plus a continuing education directory for practitioners. These resources collectively support the organization's mission to expand and protect safe, affordable state-regulated access to psychedelic healing.

Differentiator

Problem solved

Functional benefit

Products and services

• Oregon Psilocybin Program Resources Comprehensive resources explaining Oregon's state-regulated psilocybin therapy program, including client education guides, service center directories, and regulatory information for individuals seeking legal psychedelic therapy services in Oregon.
• Colorado Natural Medicine Program Resources Resources covering Colorado's Natural Medicine Health Act (Proposition 122), including healing center directories, facilitator lookup tools, and client guides for accessing supervised psychedelic-assisted therapy at licensed healing centers.
• New Mexico Medical Psilocybin Program Resources Information and advocacy resources for New Mexico's Medical Psilocybin Act, providing updates on the state's medically integrated psilocybin program development and rulemaking process.
• Psilocybin Continuing Education Directory

Quantifiable outcome

• More than 20,000 people served with an extremely low number of safety concerns
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

14 partnerships are on record, tiered core and minor.

• People SciencecoreStrategic or Co-development PartnerHAF partnered with People Science to launch an observational study examining psilocybin therapy for individuals struggling with alcohol use in Oregon. The study represents an important evolution for the field - moving beyond clinical trials into real-world research within state-regulated programs.
• InnerTrekcoreStrategic or Co-development PartnerHAF partnered with InnerTrek, an Oregon psilocybin service center, for the alcohol use disorder study. InnerTrek served as the research partner where study participants received care.
• Oregon Health & Science University (OHSU) / OPEN InitiativecoreStrategic or Co-development PartnerThe Open Psychedelic Evaluation Nexus (OPEN) at OHSU, a federally funded initiative, is conducting the first study to assess safety, implementation, and outcomes of state-regulated psilocybin services in community settings. Supported by a five-year, $3.3 million award from the National Institute on Drug Abuse.
• Psychedelic Safety InstitutecoreStrategic or Co-development PartnerHAF collaborates with the Psychedelic Safety Institute (PSI) on establishing a de-identified natural medicine data-collection system in Colorado, authorized by SB 25-297. The system will track real-world outcomes for natural medicine clients over a five-year pilot period.
• Colorado Department of Public Health and Environment (CDPHE)coreStrategic or Co-development PartnerCDPHE, in collaboration with HAF and PSI, is hosting stakeholder engagement sessions focused on establishing a data-collection system for natural medicine services.
• Mental Health ColoradominorGTM or Marketing PartnerHAF partnered with Mental Health Colorado for a panel discussion at Psycon 2026 in Denver on psychedelic safety and accountability. Experts from law enforcement, emergency medicine, and advocacy will discuss legitimate regulated care vs predatory practice.
• University of New MexicocoreStrategic or Co-development PartnerNew Mexico budget includes $300,000 for psychedelic palliative care research at UNM. The UNM Group Psilocybin-Assisted Therapy study received FDA and university approval, developed in collaboration with the Psychedelic Mental Health Access Alliance.
• Psychedelic Mental Health Access AlliancecoreStrategic or Co-development PartnerCollaborated with UNM on developing an innovative group psilocybin-assisted therapy model including community engagement, whole psilocybin mushrooms in chocolate form, group therapy with peer facilitators, and extended integration support.
• Aspen Public RadiominorGTM or Marketing PartnerHAF co-hosts the Aspen Psychedelic Symposium with Aspen Public Radio and the Aspen Psychedelic Resource Center, bringing together researchers, clinicians, cultural leaders, and community members.
• Aspen Psychedelic Resource CenterminorGTM or Marketing PartnerCo-host of the Aspen Psychedelic Symposium with HAF and Aspen Public Radio.
• Sunstone TherapiesminorStrategic or Co-development PartnerSunstone Therapies is conducting a phase 2 clinical trial studying psilocybin-assisted therapy for women with sexual assault-related PTSD. HAF highlighted this research as an example of important work in the field.
• University of CalgaryminorStrategic or Co-development PartnerUniversity of Calgary researchers are investigating psilocybin-assisted therapy for PTSD in survivors of intimate partner violence. HAF highlighted this research in their newsletter.
• National University of Natural MedicineminorStrategic or Co-development PartnerConducted a study on low-income adults with depression through Oregon's state-regulated psilocybin therapy program (LIGPATD study).
• Synaptic InstituteminorStrategic or Co-development PartnerOregon non-profit clinic dedicated to integrative mental health care and ethical use of psychedelic medicines, led by Drs. Matthew and Olivia Hicks.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Drug Policy Alliance: Drug Policy Alliance is a leading drug policy reform nonprofit working on decriminalization and regulated access, including psychedelics. Similar advocacy organization with a broader drug policy scope, sharing the state-level legislative strategy HAF employs in Oregon, Colorado, and New Mexico.
• Beckley Foundation: Beckley Foundation is a UK-based nonprofit funding psychedelic research and policy reform. Shares HAF's focus on psychedelic policy advocacy and research-driven reform, though it operates primarily in the UK and EU rather than U.S. state-level campaigns.
• Multidisciplinary Association for Psychedelic Studies (MAPS): MAPS is a 501c3 nonprofit that funds and conducts psychedelic therapy research, with parallel advocacy goals to HAF around expanding access to MDMA and other psychedelics. Both organizations share a mission to translate psychedelic research into mainstream regulated access, making MAPS the closest nonprofit peer.
• Chacruna Institute: Chacruna Institute is a nonprofit advancing psychedelic education, reciprocity, and cultural dialogue. Comparable to HAF as a psychedelic-focused nonprofit with an advocacy and education mission, alongside convening of researchers and clinicians.
• Third Wave: Third Wave is a psychedelic education and advocacy organization sharing HAF's mission to expand public awareness and access to psychedelics. Offers consumer-facing educational resources alongside HAF's policy advocacy focus, with significant overlap in audience and donor base.
• Usona Institute: Usona Institute is a nonprofit psychedelic research organization focused on psilocybin therapy for depression. Shares HAF's specific commitment to expanding psilocybin access and is a natural partner in evidence-based psychedelic therapy research and advocacy.
• Psychedelic Safety Institute: PSI is a psychedelic safety and harm reduction nonprofit working closely with HAF on Colorado's outcomes data collection system. Both organizations have aligned missions around safe, regulated access to psychedelics and frequently co-author policy and advocacy work.

Broad incumbents

• Drug Science: Drug Science is an independent scientific body on drug policy with broader scope than HAF, covering psychedelics, cannabis, and other controlled substances. Both organizations advocate for evidence-based psychedelic and drug policy reform, though Drug Science operates UK-wide and uses a science-led rather than state-legislative model.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/healing-advocacy-fund

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Healing Advocacy Fund